Moti Kashyap

List of Publications by Year
in descending order

152	11,443	28190	29081
papers	citations	55	104
		h-index	g-index

158	158	158	7373
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	6.3	1,625
2	Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events. JAMA - Journal of the American Medical Association, 2001, 285, 1585.	3.8	843
3	Interchange of Apolipoproteins between Chylomicrons and High Density Lipoproteins during Alimentary Lipemia in Man. Journal of Clinical Investigation, 1973, 52, 32-38.	3.9	500
4	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	6.3	394
5	Mechanism of Action of Niacin. American Journal of Cardiology, 2008, 101, S20-S26.	0.7	351
6	Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes. Journal of the American College of Cardiology, 2013, 62, 1575-1579.	1.2	258
7	Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism: Clinical and Experimental, 1998, 47, 1097-1104.	1.5	222
8	Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix.. American Journal of Cardiology, 2002, 89, 672-678.	0.7	221
9	Distribution of lipids in 8,500 men with coronary artery disease. American Journal of Cardiology, 1995, 75, 1196-1201.	0.7	219
10	Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. Journal of Lipid Research, 2004, 45, 1835-1845.	2.0	190
11	Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2020-2028.	1.1	189
12	Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis, 2009, 202, 68-75.	0.4	184
13	Mechanism of action of gemfibrozil on lipoprotein metabolism.. Journal of Clinical Investigation, 1985, 75, 1702-1712.	3.9	179
14	Relationship of Lipoproteins to Cardiovascular Events. Journal of the American College of Cardiology, 2013, 62, 1580-1584.	1.2	156
15	Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol. Archives of Internal Medicine, 2000, 160, 1177.	4.3	147
16	Niacin therapy in atherosclerosis. Current Opinion in Lipidology, 2004, 15, 659-665.	1.2	147
17	Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	3.7	144
18	Niacin and cholesterol: role in cardiovascular disease (review). Journal of Nutritional Biochemistry, 2003, 14, 298-305.	1.9	143

#	Article	IF	Citations
19	Radioimmunoassay of Human Apolipoprotein CII. Journal of Clinical Investigation, 1977, 60, 171-180.	3.9	137
20	Mechanism of action of niacin on lipoprotein metabolism. Current Atherosclerosis Reports, 2000, 2, 36-46.	2.0	136
21	Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis, 2007, 192, 432-437.	0.4	135
22	Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thrombosis Research, 1985, 39, 1-8.	0.8	126
23	Niacin Accelerates Intracellular ApoB Degradation by Inhibiting Triacylglycerol Synthesis in Human Hepatoblastoma (HepG2) Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1051-1059.	1.1	120
24	The mechanism and mitigation of niacin-induced flushing. International Journal of Clinical Practice, 2009, 63, 1369-1377.	0.8	115
25	Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1783-1789.	1.1	112
26	A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay. Journal of Lipid Research, 1980, 21, 491-495.	2.0	112
27	Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.. Journal of Clinical Investigation, 1986, 77, 520-527.	3.9	110
28	Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. Journal of the American Medical Directors Association, 2015, 16, 933-939.	1.2	102
29	Familial apolipoprotein A-I and C-III deficiency, variant II.. Journal of Lipid Research, 1985, 26, 1089-1101.	2.0	90
30	Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion. Artery, 1983, 12, 1-23.	1.6	89
31	Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2015, 64, 982-990.	1.5	88
32	Niacin inhibits surface expression of ATP synthase Î²2 chain in HepG2 cells: implications for raising HDL. Journal of Lipid Research, 2008, 49, 1195-1201.	2.0	86
33	The benefits of niacin in atherosclerosis. Current Atherosclerosis Reports, 2001, 3, 74-82.	2.0	84
34	Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrology Dialysis Transplantation, 2014, 29, 1554-1562.	0.4	84
35	A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay. Journal of Lipid Research, 1980, 21, 491-5.	2.0	82
36	Hyperalpha- and hypobeta-lipoproteinemia in octogenarian kindreds. Atherosclerosis, 1977, 27, 387-406.	0.4	78

#	Article	IF	Citations
37	Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.. Journal of Lipid Research, 1981, 22, 800-810.	2.0	76
38	Increased reverse cholesterol transport in athletes. Metabolism: Clinical and Experimental, 1993, 42, 684-690.	1.5	75
39	High density lipoproteinuria in nephrotic syndrome. Metabolism: Clinical and Experimental, 1976, 25, 1143-1149.	1.5	74
40	Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. Atherosclerosis, 2009, 204, 208-215.	0.4	74
41	Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial. New England Journal of Medicine, 2014, 371, 288-290.	13.9	73
42	LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. Journal of Cardiac Failure, 2018, 24, 266-275.	0.7	71
43	Familial apolipoprotein A-I and C-III deficiency, variant II. Journal of Lipid Research, 1985, 26, 1089-101.	2.0	71
44	Recent advances in niacin and lipid metabolism. Current Opinion in Lipidology, 2013, 24, 239-245.	1.2	70
45	Influence of polyunsaturated and saturated fats on plasma lipids and lipoproteins in man. American Journal of Clinical Nutrition, 1984, 39, 589-597.	2.2	65
46	Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. American Journal of Physiology - Renal Physiology, 2014, 306, G320-G327.	1.6	63
47	Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis, 1980, 35, 29-40.	0.4	60
48	Ethanol stimulates apolipoprotein A-I secretion by human hepatocytes: Implications for a mechanism for atherosclerosis protection. Metabolism: Clinical and Experimental, 1992, 41, 827-832.	1.5	60
49	Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans. Annals of Internal Medicine, 1994, 121, 252.	2.0	60
50	Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword. , 2013, 23, 203-206.		60
51	Alimentary lipemia: plasma high-density lipoproteins and apolipoproteins CII and CIII in healthy subjects. American Journal of Clinical Nutrition, 1983, 37, 233-243.	2.2	59
52	Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia. Metabolism: Clinical and Experimental, 1985, 34, 754-764.	1.5	58
53	Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. Journal of Lipid Research, 1981, 22, 800-10.	2.0	58
54	Effects of dietary carbohydrate and fat on plasma lipoproteins and apolipoproteins C-II and C-III in healthy men. Journal of Lipid Research, 1982, 23, 877-886.	2.0	56

#	Article	IF	Citations
55	Nicotinic Acid (Niacin) Receptor Agonists: Will They Be Useful Therapeutic Agents?. American Journal of Cardiology, 2007, 100, S53-S61.	0.7	55
56	Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia. American Journal of Cardiovascular Drugs, 2008, 8, 69-81.	1.0	55
57	C-II anapolipoproteinemia and severe hypertriglyceridemia. American Journal of Medicine, 1984, 77, 457-462.	0.6	53
58	Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Current Opinion in Cardiology, 2004, 19, 366-373.	0.8	51
59	Abnormal preponderance of sialylated apolipoprotein CIII in triglyceride rich lipoproteins in type V hyperlipoproteinemia. Metabolism: Clinical and Experimental, 1981, 30, 111-118.	1.5	50
60	Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus. Metabolism: Clinical and Experimental, 1989, 38, 908-912.	1.5	50
61	Relationship between Post-Heparin Plasma Lipases, Triglycerides and High Density Lipoproteins in Normal Subjects. Hormone and Metabolic Research, 1990, 22, 289-294.	0.7	48
62	Niacin, lipids, and heart disease. Current Cardiology Reports, 2003, 5, 470-476.	1.3	48
63	Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transport. American Journal of Cardiology, 1989, 63, 56-59.	0.7	46
64	Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: An in vitro model of the niacin flush. Atherosclerosis, 2007, 192, 253-258.	0.4	45
65	Mechanistic studies of high-density lipoproteins. American Journal of Cardiology, 1998, 82, 42U-48U.	0.7	44
66	Post-heparin plasma lipoprotein and hepatic lipases. Atherosclerosis, 1980, 37, 247-256.	0.4	43
67	Effects of apolipoprotein C-II (apoC-II) on the lipolysis of very low density lipoproteins from apoC-II deficient patients. Metabolism: Clinical and Experimental, 1981, 30, 818-824.	1.5	43
68	Dietitian Intervention Improves Lipid Values and Saves Medication Costs in Men with Combined Hyperlipidemia and a History of Niacin Noncompliance. Journal of the American Dietetic Association, 2000, 100, 218-224.	1.3	43
69	Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. Journal of Lipid Research, 2012, 53, 941-950.	2.0	43
70	High density lipoproteins stimulate the production and secretion of endothelin-1 from cultured bovine aortic endothelial cells.. Journal of Clinical Investigation, 1994, 93, 1056-1062.	3.9	43
71	Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 591-602.	2.2	42
72	Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metabolism: Clinical and Experimental, 1993, 42, 803-806.	1.5	41

#	Article	IF	Citations
73	Medical Nutrition Therapy Lowers Serum Cholesterol and Saves Medication Costs in Men with Hypercholesterolemia. Journal of the American Dietetic Association, 1998, 98, 889-894.	1.3	39
74	Mechanism and regulation of human intestinal niacin uptake. American Journal of Physiology - Cell Physiology, 2005, 289, C97-C103.	2.1	39
75	Effects of dietary carbohydrate and fat on plasma lipoproteins and apolipoproteins C-II and C-III in healthy men. Journal of Lipid Research, 1982, 23, 877-86.	2.0	38
76	Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?. Journal of Clinical Lipidology, 2019, 13, 873-879.	0.6	37
77	Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes. American Journal of Physiology - Cell Physiology, 2007, 293, C1773-C1778.	2.1	35
78	Pioglitazone Stimulates Apolipoprotein A-I Production Without Affecting HDL Removal in HepG2 Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2428-2434.	1.1	35
79	In vitro catabolism of human plasma very low density lipoproteins. Atherosclerosis, 1982, 41, 381-394.	0.4	34
80	Niacin: An old drug rejuvenated. Current Atherosclerosis Reports, 2009, 11, 45-51.	2.0	34
81	Hydrolysis of guinea pig nascent very low density lipoproteins catalyzed by lipoprotein lipase: activation by hjman apolipoprotein C-II.. Journal of Lipid Research, 1981, 22, 921-933.	2.0	34
82	Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line.. Journal of the American Society of Nephrology: JASN, 1994, 5, 193-200.	3.0	34
83	Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia. Pharmacotherapy, 2004, 24, 1692-1713.	1.2	33
84	Nicotinic acid: recent developments. Current Opinion in Cardiology, 2008, 23, 393-398.	0.8	33
85	Estradiol Stimulates Apolipoprotein A-Iâ€“ but Not A-Iâ€“Containing Particle Synthesis and Secretion by Stimulating mRNA Transcription Rate in Hep G2 Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 999-1006.	1.1	31
86	Gemfibrozil Stimulates Apolipoprotein A-I Synthesis and Secretion by Stabilization of mRNA Transcripts in Human Hepatoblastoma Cell Line (Hep G2). Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1052-1062.	1.1	28
87	Reverse D4F, an Apolipoprotein-AI Mimetic Peptide, Inhibits Atherosclerosis in ApoE-null Mice. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 334-343.	1.0	27
88	Composition of HDL-2 and HDL-3 in familial hyperalphalipoproteinemia. Atherosclerosis, 1976, 25, 131-136.	0.4	26
89	Carbohydrate and lipid metabolism during human labor: Free fatty acids, glucose, insulin, and lactic acid metabolism during normal and oxytocin-induced labor for postmaturity. Metabolism: Clinical and Experimental, 1976, 25, 865-875.	1.5	25
90	Niacin extended-release/ lovastatin: combination therapy for lipid disorders. Expert Opinion on Pharmacotherapy, 2002, 3, 1763-1771.	0.9	25

#	Article	IF	Citations
91	Management of the metabolic syndromeâ€"nicotinic acid. Endocrinology and Metabolism Clinics of North America, 2004, 33, 557-575.	1.2	25
92	Niacin and Progression of CKD. American Journal of Kidney Diseases, 2015, 65, 785-798.	2.1	24
93	The role of high density lipoprotein apolipoprotein CII in triglyceride metabolism. Lipids, 1978, 13, 933-942.	0.7	23
94	Cardiovascular disease in the elderly: Current considerations. American Journal of Cardiology, 1989, 63, 3-4.	0.7	23
95	Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. Atherosclerosis, 2002, 164, 221-228.	0.4	23
96	Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells. Journal of Lipid Research, 2010, 51, 2211-2222.	2.0	23
97	Lipoprotein lipase activator deficiency in very low density lipoproteins in rat nephrotic syndrome. Experientia, 1978, 34, 1044-1045.	1.2	21
98	Human plasma lipid transfer protein catalyzes the speciation of high density lipoproteins. Lipids and Lipid Metabolism, 1987, 918, 260-266.	2.6	21
99	Renal handling of high-density lipoproteins by isolated perfused kidneys. Metabolism: Clinical and Experimental, 1984, 33, 432-438.	1.5	20
100	Effect of niacin on lipoproteins and atherosclerosis. Future Lipidology, 2006, 1, 549-557.	0.5	20
101	Baseline Achievement of Lipid Goals and Usage of Lipid Medications in Patients With Diabetes Mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology, 2006, 98, 63-65.	0.7	20
102	Inverse Association Between Serum Nonâ€"Highâ€Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. Journal of the American Heart Association, 2018, 7, .	1.6	20
103	Diet and HDL Metabolism: High Carbohydrate vs. High Fat Diets. Advances in Experimental Medicine and Biology, 1987, 210, 165-172.	0.8	20
104	High-Density Lipoprotein Apolipoprotein AI and AII Turnover in Moderate and Severe Proteinuria. Nephron, 1988, 50, 112-115.	0.9	19
105	Association of Serum Lipids with Outcomes in Hispanic Hemodialysis Patients of the West versus East Coasts of the United States. American Journal of Nephrology, 2015, 41, 284-295.	1.4	19
106	Comparison of gradient gel electrophoresis and zonal ultracentrifugation for quantitation of high density lipoproteins. Journal of Lipid Research, 1985, 26, 1363-1367.	2.0	19
107	Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia. American Journal of Cardiovascular Drugs, 2009, 9, 69-79.	1.0	18
108	Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Metabolism: Clinical and Experimental, 2008, 57, 973-979.	1.5	17

#	Article	IF	Citations
109	Mammalian colonocytes possess a carrier-mediated mechanism for uptake of vitamin B3 (niacin): studies utilizing human and mouse colonic preparations. American Journal of Physiology - Renal Physiology, 2013, 305, G207-G213.	1.6	17
110	Niacin decreases leukocyte myeloperoxidase: Mechanistic role of redox agents and Src/p38MAP kinase. Atherosclerosis, 2014, 235, 554-561.	0.4	17
111	Comparison of gradient gel electrophoresis and zonal ultracentrifugation for quantitation of high density lipoproteins. Journal of Lipid Research, 1985, 26, 1363-7.	2.0	17
112	Dietary fat in experimental nephrotic syndrome: Beneficial effects of fish oil on serum lipids and, indirectly, on the kidney. Life Sciences, 1987, 40, 2317-2324.	2.0	16
113	Optimal Therapy of Low Levels of High Density Lipoprotein-Cholesterol. American Journal of Cardiovascular Drugs, 2003, 3, 53-65.	1.0	15
114	Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. Journal of Clinical Lipidology, 2018, 12, 488-497.	0.6	15
115	Plasma Lipids and Lipoprotein Lipase Activator Property during the Menstrual Cycle. Hormone and Metabolic Research, 1979, 11, 696-697.	0.7	14
116	Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Current Opinion in Internal Medicine, 2005, 4, 517-522.	1.5	14
117	Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4848-4856.	1.8	14
118	Synovial fluid lipoproteins: Review of current concepts and new directions. Seminars in Arthritis and Rheumatism, 1993, 23, 79-89.	1.6	13
119	Statin Therapy Before Transition to Endâ€Stage Renal Disease With Posttransition Outcomes. Journal of the American Heart Association, 2019, 8, e011869.	1.6	13
120	Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. Metabolism: Clinical and Experimental, 1994, 43, 665-669.	1.5	12
121	Myeloperoxidase and Atherosclerosis. Current Cardiovascular Risk Reports, 2013, 7, 102-107.	0.8	12
122	Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: Rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS). American Journal of Cardiology, 1995, 76, 1239-1242.	0.7	10
123	Identification of an apoC-II variant (apoC-IIBethesda) in a kindred with apoC-II deficiency and type I hyperlipoproteinemia.. Journal of Lipid Research, 1988, 29, 273-278.	2.0	10
124	Octogenarian kindred: Hyper-Î±-lipoproteinemia. Preventive Medicine, 1978, 7, 1-14.	1.6	9
125	Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism. Kidney International, 1996, 50, 2079-2087.	2.6	9
126	Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease. Journal of the Endocrine Society, 2019, 3, 1869-1880.	0.1	9

#	Article	IF	Citations
127	Apolipoprotein CII in type I hyperlipoproteinemia. A study in three cases. Translational Research, 1980, 95, 180-7.	2.4	9
128	A micromethod using gas-liquid chromatography for measuring individual fatty acids liberated during interaction of triglyceride-rich lipoproteins and lipoprotein lipase. Analytical Biochemistry, 1980, 107, 432-435.	1.1	8
129	Effect of desialylation of very low-density lipoproteins on their catabolism by lipoprotein lipase. Metabolism: Clinical and Experimental, 1985, 34, 30-35.	1.5	8
130	Characterization of high density lipoproteins from patients with severe hypertriglyceridemia. Atherosclerosis, 1987, 66, 37-43.	0.4	8
131	Albumin inhibits apolipoprotein AI and AII production in human hepatoblastoma cell line (Hep G2): additive effects of oleateâ€“albumin complex. Atherosclerosis, 2000, 149, 43-49.	0.4	8
132	Familial Hypertriglyceridemia in Children: Dietary Management. Pediatric Research, 1977, 11, 953-957.	1.1	7
133	Late hypertriglyceridemia in very low birth weight infants fed human milk exclusively. Journal of Pediatrics, 1987, 111, 466-469.	0.9	7
134	HDL Metabolism in HDL Deficiency Associated with Familial Hypertriglyeridemia: Effect of Treatment with Gemfibrozil. Advances in Experimental Medicine and Biology, 1990, 285, 233-236.	0.8	7
135	Role of adipose tissue in free fatty acid metabolism in hemorrhagic hypotension and shock. Metabolism: Clinical and Experimental, 1975, 24, 855-860.	1.5	6
136	Effect of a high carbohydrate diet on the content of apolipoproteins C-II, C-III and E in human plasma high density lipoprotein subfractions. Atherosclerosis, 1983, 46, 341-352.	0.4	6
137	Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events. American Journal of Cardiovascular Drugs, 2011, 11, 179-187.	1.0	6
138	Catabolism of human very low density lipoproteins in vitro: a fluorescent phospholipid method for monitoring lipolysis.. Journal of Lipid Research, 1981, 22, 382-386.	2.0	6
139	Catabolism of human very low density lipoproteins in vitro: a fluorescent phospholipid method for monitoring lipolysis. Journal of Lipid Research, 1981, 22, 382-6.	2.0	6
140	Plasma lipids and lipoprotein lipase activating property in women on three different combinations of estrogens and progestins. Biochemical Medicine, 1981, 25, 283-287.	0.5	5
141	Characterization of a monoclonal antibody (HB-22) and development of an ELISA for human apolipoprotein A-I. Clinical Chemistry, 1995, 41, 1150-1158.	1.5	5
142	Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort. Journal of Clinical Lipidology, 2018, 12, 1413-1419.	0.6	5
143	Effect of human high density lipoproteins, anti-apolipoproteins CII and CIII, and hydrolysis of very low density lipoprotein (VLDL) cholesterol ester on VLDL catabolism in vitro. Biochemical and Biophysical Research Communications, 1984, 121, 946-952.	1.0	3
144	[12] Immunochemical methods for quantification of human apolipoprotein C-III. Methods in Enzymology, 1996, 263, 208-218.	0.4	3

#	Article	IF	Citations
145	Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert Review of Cardiovascular Therapy, 2008, 6, 1303-1310.	0.6	3
146	Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 534-541.	1.0	3
147	Tissue lipoprotein lipase, serum, and urinary lipids and lipoproteins in experimental glomerulonephritis of rats (Heymann's nephritis). Biochemical Medicine, 1981, 25, 260-266.	0.5	2
148	Kinetics of lipoprotein lipase interaction with triacylglycerol-rich lipoproteins carrying excess apolipoprotein C-III2. Biochemical Society Transactions, 1985, 13, 131-132.	1.6	2
149	Clinical utility and methods for assessing triglyceride-rich lipoprotein metabolism. Current Opinion in Lipidology, 1991, 2, 379-384.	1.2	2
150	Dyslipidemia treatment: current considerations and unmet needs. Expert Review of Cardiovascular Therapy, 2003, 1, 121-134.	0.6	0
151	Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. Future Cardiology, 2005, 1, 461-471.	0.5	0
152	Diet and High-Density Lipoprotein Metabolism. , 1987, , 557-562.		0